Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
Condition(s):NASH – Nonalcoholic Steatohepatitis; Diabetes Mellitus, Type 2Last Updated:February 23, 2024Active, not recruiting